O

Ondine Biomedical Inc
LSE:OBI

Watchlist Manager
Ondine Biomedical Inc
LSE:OBI
Watchlist
Price: 10.8 GBX 2.86%
Market Cap: 47.9m GBX

Wall Street
Price Targets

OBI Price Targets Summary
Ondine Biomedical Inc

Wall Street analysts forecast OBI stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for OBI is 56.1 GBX with a low forecast of 55.55 GBX and a high forecast of 57.75 GBX.

Lowest
Price Target
55.55 GBX
414% Upside
Average
Price Target
56.1 GBX
419% Upside
Highest
Price Target
57.75 GBX
435% Upside
Ondine Biomedical Inc Competitors:
Price Targets
IDXX
IDEXX Laboratories Inc
1% Upside
BSX
Boston Scientific Corp
20% Upside
STXS
Stereotaxis Inc
118% Upside
SRT
Sartorius AG
77% Upside
ISRG
Intuitive Surgical Inc
16% Upside
6869
Sysmex Corp
33% Upside
METN
Metall Zug AG
3% Upside
EW
Edwards Lifesciences Corp
10% Upside

Revenue
Forecast

Revenue Estimate
Ondine Biomedical Inc

For the last 2 years the compound annual growth rate for Ondine Biomedical Inc's revenue is -32%. The projected CAGR for the next 4 years is 136%.

-32%
Past Growth
136%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
Ondine Biomedical Inc

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Net Income
Forecast

Net Income Estimate
Ondine Biomedical Inc

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is OBI's stock price target?
Price Target
56.1 GBX

According to Wall Street analysts, the average 1-year price target for OBI is 56.1 GBX with a low forecast of 55.55 GBX and a high forecast of 57.75 GBX.

What is Ondine Biomedical Inc's Revenue forecast?
Projected CAGR
136%

For the last 2 years the compound annual growth rate for Ondine Biomedical Inc's revenue is -32%. The projected CAGR for the next 4 years is 136%.

Back to Top